Recurrent Implantation Failure. Female infertility of uterin
Conditions
Interventions
Intervention 1: Prescription of Tacrolimus in the second menstrual cycle for up to 16 days (until 2 days before second biopsy) with 1-3 mg per day upon on IFN-g/IL-4 ratio:
Prescription of 1 mg per d
Treatment - Drugs
Prescription of Tacrolimus in the second menstrual cycle for up to 16 days (until 2 days before second biopsy) with 1-3 mg per day upon on IFN-g/IL-4 ratio:
Prescription of 1 mg per day if this rati
Prescription of Tacrolimus in third cycle of menstruation from 2 days before embryo transfer until 14 days after embryo transfer for overall 16 days with 1-3 mg per day upon on IFN-g/IL-4 ratio.
Pr
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: History of 3 or more failed IVF/ET cycles with morphologically and developmentally average to good-quality embryo( 7 or more blastomeres and less than 10% fragmentation in day 3 ) into an adequately prepared endometrium (endometrial thickness equal or more than 8 mm); Women who had regular menses (25 to 35 days); Women who had normal karyotype; women who had at least one of these Immunological disorders in their peripheral blood sample between day of 5 to 10 of menstrual cycle: IFN-g/IL-4 equal or more than 10.3 or Nk-cell percentage greater than 12%
Exclusion criteria
Exclusion criteria: Present of sub mucosal fibroids, endometrial polyps, intrauterine adhesions, congenital anomalies of uterus or hydrosalpinges History of active autoimmune disease (With assessment of ANA, Anti-TG, Anti-TPO, Anti-dsDNA); Women with acquired or inherited thrombophilia (With assessment of Factor2, Factor5, Factor 8, Fibrinogen, Anti- Cardiolipin, Anti-Phospholipid Antibody, Lupus Anti-Coagulate, s-MTHFR gene) Pregnant women; History of miscarriage in a former IVF/ET cycle; Women who received vaccine in the last three months; Women who received steroid hormones in the last 2 months; Women receiving immunotherapy; Women with chronic inflammatory diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of P53 gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of LIF gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of IL-10 gene. Timepoint: Measure Twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of IL-17 gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| LIF protein levels in uterine fluid. Timepoint: Measure twice: before and after treatment. Method of measurement: ELISA.;Level Of IL-10 protein in uterine fluid. Timepoint: Measure twice: before and after treatment. Method of measurement: ELISA.;Level Of IL-17 protein in uterine fluid. Timepoint: Measure twice: before and after treatment. Method of measurement: ELISA.;Biochemical Pregnancy Rate. Timepoint: Two weeks after embryo transfer. Method of measurement: Level of B-HCG in blood.;Live Birth Rate. Timepoint: Nine months after embryo transfer. Method of measurement: Number of newborns.;Embryo implantation Rate. Timepoint: Two weeks after a chemical pregnancy confirmation. Method of measurement: Observation of Pregnancy Sac by Ultrasound.;Blood level of Estradiol. Timepoint: Measure twice: before and after treatment. Method of measurement: Measurement in blood.;Blood level of Progestron. Timepoint: Measure twice: before and after treatment. Method of measurement: Measurement in blood.;P53 protein level in endometrium. Timepoint: Measure twice: before and after treatment. Method of measurement: immunohistochemistry.;LIF protein level in endometrium. Timepoint: Measure twice: before and after treatment. Method of measurement: immunohistochemistry.;IL-10 protein level in endometrium. Timepoint: Measure twice: before and after treatment. Method of measurement: immunohistochemistry.;IL-17 protein level in endometrium. Timepoint: Measure twice: before and after treatment. Method of measurement: immunohistochemistry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Bahrami Asl
Shahid Beheshti University of Medical Sciences
Outcome results
None listed